[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:hla-a-gene":3},{"name":4,"total":5,"recruiting":6,"trials":7},"HLA-A Gene",18,15,[8,16,22,29,36,42,48,54,60,66,73,79,85,91,97,103,109,115],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06043713","Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations",[12],"Phase 1","RECRUITING","2026-08-26T02:16:45.157238Z","2026-07-19T19:36:05.129956Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT03943238","TLI, TBI, ATG & Hematopoietic Stem Cell Transplantation and Recipient T Regs Therapy in Living Donor Kidney Transplantation",[12],"2026-08-26T02:16:47.762107Z","2026-07-05T03:45:20.247624Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT06246149","Adjuvant Tebentafusp in High Risk Ocular Melanoma",[26],"Phase 3","2026-08-26T02:17:07.954622Z","2026-07-05T03:45:20.245754Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT06066359","Ph I\u002FII Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR\u002FIL-15 for R\u002FR Myeloma",[33],"Phase 1\u002FPhase 2","2026-08-26T02:17:58.890423Z","2026-06-18T04:29:21.268683Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT05417932","A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma",[33],"2026-08-26T02:18:00.873391Z","2026-05-05T02:43:27.511518Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT05473910","A Phase 1\u002F3 Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA-2)",[12],"2026-08-26T02:16:50.548894Z","2026-07-19T19:36:05.117931Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT07594067","TCR1188-ABC Cells in KRAS-mutated Cancers",[12],"2026-08-26T02:16:38.053590Z","2026-07-19T19:36:05.077181Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT06083883","Phase I\u002FIb Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1",[12],"2026-08-26T02:18:26.129155Z","2026-04-29T02:57:57.066842Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT05877599","A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation",[12],"2026-08-26T02:15:10.362237Z","2026-07-19T19:36:05.120541Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":71,"content_modified":72},"NCT05686226","E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers",[70],"Phase 2","2026-08-26T02:15:28.524219Z","2026-07-05T05:32:16.812867Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06315309","Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant",[70],"2026-08-26T02:16:48.735701Z","2026-05-05T02:43:29.662218Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT06218914","Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and\u002For Metastatic Solid Tumors",[12],"2026-08-26T02:15:14.574786Z","2026-05-05T02:43:28.813182Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT03190941","Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients",[33],"2026-08-26T02:18:06.247899Z","2026-05-05T02:43:28.129328Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT07645469","FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia",[12],"2026-08-26T02:17:38.215063Z","2026-06-14T18:39:22.265217Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT07638371","A Study of MSK-TCR5 in People With Solid Tumor Cancers",[12],"2026-08-26T02:18:29.369233Z","2026-06-14T18:39:22.257001Z",{"nct_id":104,"title":105,"phases":106,"status":107,"updated_at":71,"content_modified":108},"NCT07583303","BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation",[12],"NOT_YET_RECRUITING","2026-05-29T15:36:40.194501Z",{"nct_id":110,"title":111,"phases":112,"status":107,"updated_at":113,"content_modified":114},"NCT07650357","A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)",[12],"2026-08-26T02:18:46.948970Z","2026-06-17T02:29:30.058689Z",{"nct_id":116,"title":117,"phases":118,"status":119,"updated_at":120,"content_modified":121},"NCT07007117","PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T03:12:56.078888Z","2026-05-05T02:43:29.470387Z"]